United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

4:00pm EDT
Change (% chg)

$0.22 (+0.60%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for PFE.N


Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor,... (more)


Beta: 0.83
Market Cap(Mil.): $222,398.00
Shares Outstanding(Mil.): 6,064.85
Dividend: 0.30
Yield (%): 3.27


  PFE.N Industry Sector
P/E (TTM): 30.05 39.19 39.69
EPS (TTM): 1.22 -- --
ROI: 5.56 15.23 14.44
ROE: 11.65 16.16 15.49

BRIEF-Sanofi, Pfizer, Gilead & Celgene interested in Medivation - CNBC citing sources

* Sanofi, Pfizer, Gilead & Celgene interested in Medivation as company asks for indications of interest by mid-August - CNBC citing sources Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

9:40am EDT

BRIEF-Bind Therapeutics says it entered into an asset purchase agreement with Pfizer

* Says amendment to increase the purchase price of the acquisition to $40 million

Jul 28 2016

BRIEF-Pfizer announces positive top-line results from Phase 3 Maintenance Trial of Oral XELJANZ

* No new or unexpected safety findings for Tofacitinib were observed in study

Jul 28 2016

BRIEF-Pfizer and Western Oncolytics announce immuno-oncology research collaboration

* Pfizer and Western Oncolytics announce immuno-oncology research collaboration to investigate novel oncolytic virus technology

Jul 28 2016

AstraZeneca helped by new drugs as cholesterol pill fades

LONDON Generic competition to cholesterol buster Crestor in the U.S. market pushed second-quarter core earnings down by nearly a third at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes.

Jul 28 2016

UPDATE 2-AstraZeneca helped by new drugs as cholesterol pill fades

* New drug Tagrisso sold better-than-expected $92 mln in Q2 (Adds CEO comments on upcoming clinical data and M&A)

Jul 28 2016

AstraZeneca a takeover target again? CEO not commenting

LONDON, July 28 AstraZeneca declined to comment on Thursday on whether the drugmaker could become a takeover target once more, two years after it saw off a bid from Pfizer.

Jul 28 2016

UPDATE 2-Incoming Lilly CEO says dealmaking will be a focus

July 27 Eli Lilly & Co will likely step up the pace of making deals with other drugmakers while aggressively developing new drugs on its own, the company's newly appointed chief executive said on Wednesday.

Jul 27 2016

Bayer drugs secure earnings beat, offset weak crop chems

FRANKFURT Bayer , the German drugmaker trying to acquire U.S. seed company Monsanto , surpassed second-quarter earnings expectations and raised its guidance for the year as strong gains in stroke prevention pill Xarelto offset sluggish farming pesticides markets.

Jul 27 2016

UPDATE 1-Bayer drugs secure earnings beat, offset weak crop chems

* Shares seen up 0.7 pct in premarket trades (Adds details on Xarelto, Eylea, Crop Chemicals unit, background on Monsanto)

Jul 27 2016


  Price Chg
Johnson & Johnson (JNJ.N) $125.23 +0.77
Novartis AG (NOVN.S) CHF80.30 0.00
Merck & Co., Inc. (MRK.N) $58.66 +0.23
Roche Holding Ltd. (ROG.S) CHF247.50 +2.00
Roche Holding Ltd. (RO.S) CHF249.60 +1.80
Abbott Laboratories (ABT.N) $44.75 +0.30
Bayer AG (BAYGn.DE) €96.22 +1.91
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.15 -0.14
AstraZeneca plc (AZN.L) 5,048.00p +21.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : Wright Reports
Provider : MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.